Paris (France) and Cambridge (Massachusetts, USA), February 27, 2026 – Biophytis SA (Euronext Growth Paris: ALBPS), (“the Company”), a pioneering company in the development of transformative therapies impacting longevity, announces several amendments to its bond financing initially announced on August 5, 2025, in mutual agreement with Hexagon Capital Fund.
Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity
Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the…
